BMY’s robust launch portfolio, resilient free cash flow, and above-consensus growth outlook position it for outsized returns ...

Shares of this biotech giant have lost 16.3% year to date compared with the industry’s decline of 2.7%. The stock has also ...

Bonilla, MD, MSEd, discusses 5-year data from the phase 3 CheckMate 577 trial, presented at the 2025 ASCO Annual Meeting.

PFE's robust late-stage pipeline, recent FDA wins and deep oncology bets position it for long-term growth through 2030.

Oral cancer, which includes malignancies affecting the lips, tongue, gums, cheeks, and floor of the mouth, represents a ...

Amgen acquired Five Prime in 2021 on the back of the phase 2 FIGHT trial of bemarituzumab, which achieved significant ...

Bristol Myers Squibb Company (NYSE:BMY – Get Free Report) has received an average rating of “Hold” from the twenty-two brokerages that are presently covering the firm, MarketBeat reports. Two ...

Bristol-Myers Squibb faces patent losses and growth headwinds despite pipeline gains, debt cuts, and dividends. Read why BMY ...

BMS’ Opdivo, used in combination with chemotherapy, is now allowed in advanced or metastatic gastric, gastroesophageal junction (GEJ) and esophageal cancers only among patients whose tumors ...

Dr. Michael Serzan explains the importance of clinical trial enrollment for patients with kidney cancer and highlighted findings from the STELLA-002 trial.

The Opdivo/Yervoy combination was just one positive trial in melanoma reported at ASCO, with other studies showing the progress made in tackling a disease that, until recently, ...

June brought genitourinary cancer updates, and CURE is sharing the latest in kidney cancer treatment, as well as FDA ...